Upon completion of the activity, participants should be able to:
This educational initiative is intended for Endocrinologists/members of the Primary Care Team.
The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.
The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.
First
MI
Last
Credentials
Position
Institution
Role
Disclosure(s)
Samantha
R.
Harris
MD
Endocrinologist
Scripps Clinic Medical Group, Center for Weight Management
Moderator
Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
Scott
D.
Isaacs
MD, FACP, FACE
Adjunct Assistant Professor of Medicine
Emory University School of Medicine
Speaker
Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Medpace (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Quest (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21)
Kenneth
Cusi
Chief of the Division of Endocrinology
UFL
Allergan Pharmaceuticals (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Axcellla (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); BMS (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Cirius (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Coherus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Deuterex (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Echosens (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Fractyl (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genentech (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genfit (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); High Tide (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2021); Inventiva (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Janssen (Self) : Research Grant (Status: Terminated --- 2020); Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); National Institutes of Health (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Nordic (Self) : Research Support (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Poxel (Self) : Research Grant (Status: Terminated --- 2021); Prosciento (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi-Adventis (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Viscera Labs (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Zydus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
Martin
M.
Grajower
Clinical Professor of Medicine
Albert Einstein College of Medicine
Abbott/AbbVie (Self) : Honorarium (Status: Terminated --- 10/01/2021); Bayer (Self) : Honorarium (Status: Ongoing); echosense (Self) : Honorarium (Status: Ongoing); Novo Nordisk (Self) : Honorarium (Status: Ongoing)
Amy
Fischl
MS, RDN, LDN, BC-ADM, CDCES
University of Chicago
Abbott Diabetes Care (Self) : Honorarium (Status: Ongoing); Xeris Pharmaceuticals (Self) : Honorarium (Status: Ongoing)
AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.